150 related articles for article (PubMed ID: 7547212)
1. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
Zilembo N; Noberasco C; Bajetta E; Martinetti A; Mariani L; Orefice S; Buzzoni R; Di Bartolomeo M; Di Leo A; Laffranchi A
Br J Cancer; 1995 Oct; 72(4):1007-12. PubMed ID: 7547212
[TBL] [Abstract][Full Text] [Related]
2. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
3. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
4. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
Lombardi P
Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
[TBL] [Abstract][Full Text] [Related]
5. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
6. Exemestane in advanced breast cancer.
Buzdar A
Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
[TBL] [Abstract][Full Text] [Related]
7. Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
di Salle E; Ornati G; Giudici D; Lassus M; Evans TR; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):137-43. PubMed ID: 1525055
[TBL] [Abstract][Full Text] [Related]
8. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
9. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G; Gangadhara S
Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
Zaccheo T; Giudici D; Ornati G; Panzeri A; di Salle E
Eur J Cancer; 1991; 27(9):1145-50. PubMed ID: 1835626
[TBL] [Abstract][Full Text] [Related]
11. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Evans TR; Di Salle E; Ornati G; Lassus M; Benedetti MS; Pianezzola E; Coombes RC
Cancer Res; 1992 Nov; 52(21):5933-9. PubMed ID: 1394219
[TBL] [Abstract][Full Text] [Related]
12. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
[TBL] [Abstract][Full Text] [Related]
13. Overview of the pharmacology of the aromatase inactivator exemestane.
Brueggemeier RW
Breast Cancer Res Treat; 2002 Jul; 74(2):177-85. PubMed ID: 12186378
[TBL] [Abstract][Full Text] [Related]
14. Exemestane: treatment of breast cancer with selective inactivation of aromatase.
Higa GM
Am J Health Syst Pharm; 2002 Nov; 59(22):2194-2201; quiz 2202-4. PubMed ID: 12455303
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].
Tahara M; Nomura S; Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):345-54. PubMed ID: 14501171
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
[TBL] [Abstract][Full Text] [Related]
17. Drug safety evaluation of exemestane.
Lintermans A; Neven P; Paridaens R
Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
[TBL] [Abstract][Full Text] [Related]
18. Exemestane: a novel aromatase inactivator for breast cancer.
Jones SA; Jones SE
Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
[TBL] [Abstract][Full Text] [Related]
19. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Di Leo A; Bartoli C; Merson M; Sacchini V; Moglia D; Celio L
Br J Cancer; 1994 Jul; 70(1):145-50. PubMed ID: 8018527
[TBL] [Abstract][Full Text] [Related]
20. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
